Scanning for PSMA
Why Scan for PSMA?
More than 80% of patients with prostate cancer are PSMA+, making PSMA an ideal diagnostic and therapeutic target1-5
PSMA is a transmembrane protein that is overexpressed on prostate cancer cells6
PSMA+ lesions can be visualized using PSMA positron emission tomography (PET)7,8
Knowing your patient is PSMA+ may enable you to offer PLUVICTO, a PSMA-targeted radioligand therapy (RLT)7-9
CT, computed tomography; PSMA, prostate specific membrane antigen; PSMA+, PSMA positive.
Scanning to Determine PSMA Status
PSMA scanning helps you see and target PSMA+ mCRPC7-9
PSMA PET demonstrates high sensitivity and specificity to see PSMA+ metastases7-10
Once a scan confirms PSMA+ mCRPC, the disease* can be treated with PLUVICTO wherever it has spread—bone, nodal, and visceral metastases7,9,11
>80% of men with prostate cancer are PSMA+, making PSMA an ideal diagnostic and therapeutic target.1-5
*Please see full indication for further details.
Scan to determine PSMA status. Knowing your patient who has received an ARPI and taxane is PSMA+ enables you to offer a PSMA-targeted RLT.6
ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer.
Patients in Your Practice Who May Benefit From PLUVICTO
Patients with PSMA+ metastases on PSMA PET/CT scan have been shown to benefit from PLUVICTO6
Consider a PSMA PET/CT for patients in your practice with mCRPC6,12
ADT, androgen deprivation therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; mHSPC, metastatic hormone-sensitive prostate cancer; OS, overall survival; PSA, prostate-specific antigen.
a Product used as directed by product Prescribing Information/label.
What is your next step for patients like Stan?
BCR, biochemical recurrence; nmCRPC, nonmetastatic castration-resistant prostate cancer; PC, prostate cancer; PSADT, prostate-specific antigen doubling time.
a Product used as directed by product Prescribing Information/label.
What is your next step for patients like Maurice?
What is your next step for patients like José?
What is your next step for patients like Elliot?
See how PLUVICTO helped patients like this in the VISION trial